Crucell signs European STAR licensing agreement

By Lisa Kerner

Charlotte, N.C., Sept. 7 - Crucell NV signed its first European STAR licensing agreement with UCB, which will evaluate the technology using its proprietary mammalian CHO cell line.

The five-year agreement covers a non-exclusive research license for the production of monoclonal antibodies.

Under the agreement, the Brussels, Belgium-based UCB will pay a license issuance fee, milestone fees and annual maintenance fees to Crucell.

Further financial details were not disclosed.

Crucell is a biotechnology company located in Leiden, The Netherlands.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.